Patents by Inventor Jayaram K. Srirangam
Jayaram K. Srirangam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7022846Abstract: Metabolites of a matrix metalloproteinase inhibitor prinomastat and their synthesis. These metabolites are: (3S)-N-hydroxy-4-(4-((1-oxy-pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide (M6); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(1-oxy-pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M7); (3S)-2,2-dimethyl-4-[4-(1-oxypyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M8); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M2); and (3S)-2,2-dimethyl-4-[4-(pyridin-4yloxy)-benzenesulfonyl)-thiomorphpline-3-carboxylic acid amide (M3).Type: GrantFiled: June 10, 2003Date of Patent: April 4, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael A. Ouellette, Barbara C. M. Potts, Jayaram K. Srirangam, Anthony R. Tibbetts, Kanyin E. Zhang
-
Publication number: 20040053922Abstract: Metabolites of a matrix metalloproteinase inhibitor prinomastat and their synthesis. These metabolites are: (3S)-N-hydroxy4-(4-((1-oxy-pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide (M6); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(1-oxy-pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M7); (3S)-2,2-dimethyl-4-[4-(1-oxypyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M8); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M2); and (3S)-2,2-dimethyl-4-[4-(pyridin-4yloxy)-benzenesulfonyl)-thiomorphpline-3-carboxylic acid amide (M3).Type: ApplicationFiled: June 10, 2003Publication date: March 18, 2004Applicant: Agouron Pharmaceuticals, Inc.Inventors: Michael A. Ouellette, Barbara C.M. Potts, Jayaram K. Srirangam, Anthony R. Tibbetts, Kanyin E. Zhang
-
Patent number: 6323315Abstract: The present invention provides compounds of the formula where R1-R5 are each, independently, a hydrogen atom or a normal or branched C1-C6-alkyl group; A is a methionyl, phenylalanyl or phenylglycyl residue; n is 0 or 1; R6 is a hydrogen atom; and R7 is a carbocylic group, an aromatic group, a C1-C4-alkyl group, a pyridylalkyl group or a heterocyclic group. In another embodiment, R6 is benzyl or —C(O)OR8, where R8 is a C1-C6-alkyl group, and R7 is a heteroaromatic group, such as a 2-thiazolyl group.Type: GrantFiled: March 31, 2000Date of Patent: November 27, 2001Assignees: BASF Aktiengesellschaft, Arizona Board of RegentsInventors: George R. Pettit, Jayaram K. Srirangam, Michael D. Williams, Kieran P. M. Durkin, Teresa Barlozzari, Andreas Kling, Bernd Janssen, Andreas Haupt
-
Patent number: 5780588Abstract: The sea hare Dolabella auricularia has yielded many structurally distinct peptides which possess antineoplastic activity. Presently the compound denominated "dolastatin 10" represents the most important of such peptides because of its demonstrated potential as an anticancer drug.The present invention relates to the systematic creation of five unique pentapeptides by selectively coupling a tripeptide-trifluoroacetate salt with a preselected dipeptide-trifluoroacetate salt which provide active molecules capable of emulating the measured therapeutic effect of dolastatin 10.Type: GrantFiled: January 26, 1993Date of Patent: July 14, 1998Assignee: Arizona Board of RegentsInventors: George R. Pettit, Jayaram K. Srirangam
-
Patent number: 5665860Abstract: This application discloses seven newly synthesized pentapeptide amides and our tetrapeptide amides. The synthesis utilized both naturally occurring and modified amino acids; the modified amino acids are constituents of the well known dolastatin 10 and dolastatin 15 which are structurally distinct peptides with excellent antineoplastic activity. These peptides were constructed by introducing a peptide bond between selected amino acids and modified amino acids and coupling the resulting di- and tri-peptides to obtain peptides having a high anticancer activity against a series of human cancer cell lines.Type: GrantFiled: June 13, 1996Date of Patent: September 9, 1997Assignee: Arizona Board of Regents acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam, Michael D. Williams
-
Patent number: 5663149Abstract: The synthesis and elucidation of nineteen heterocyclic or halophenyl amide erivatives of dolastatin 10 are disclosed. These compounds and the methods of producing those compounds offer demonstrated significant in vitro activity against several human cancer cell lines. These compounds and the methods of producing those compounds offer a commercially viable alternative to natural and synthetic dolastatin 10.Type: GrantFiled: December 13, 1994Date of Patent: September 2, 1997Assignee: Arizona Board of Regents acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam, Darko Kantoci
-
Patent number: 5599902Abstract: The sea hare Dolabella auricularia has yielded many structurally distinct ptides which possess antineoplastic activity. Presently the compound denominated "dolastatin 10" represents the most important of such peptides because of its demonstrated potential as an anticancer drug.The present invention relates to the systematic creation of seven unique pentapeptides by selectively coupling a tripeptide-trifluoroacetate salt with a preselected dipeptide trifluoroacetate salt which provide active molecules capable of emulating the measured therapeutic effect of dolastatin 10.Type: GrantFiled: November 10, 1994Date of Patent: February 4, 1997Assignee: Arizona Board of Regents acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam
-
Patent number: 5530097Abstract: This application discloses seven newly synthesized pentapeptide amides and our tetrapeptide amides. The synthesis utilized both naturally occurring and modified amino acids; the modified amino acids are constituents of the well known dolastatin 10 and dolastatin 15 which are structurally distinct peptides with excellent antineoplastic activity. These peptides were constructed by introducing a peptide bond between selected amino acids and modified amino acids and coupling the resulting di- and tri-peptides to obtain peptides having a high anticancer activity against a series of human cancer cell lines.Type: GrantFiled: August 1, 1994Date of Patent: June 25, 1996Assignee: Arizona Board of Regents acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam, Michael D. Williams
-
Patent number: 5521284Abstract: The isolation, elucidation and synthetic replication of novel pentapeptide mides and esters are described. The compounds have the general structure ##STR1## in which R.sub.1 and R.sub.2 are selected as shown below: ##STR2##R.sub.1 =CH.sub.3 ; R.sub.2 =--O--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 16a)R.sub.1 =CH.sub.3 ; R.sub.2 =--O--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 16b)R.sub.1 =CH.sub.3 ; R.sub.2 =--NH--CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.Type: GrantFiled: August 1, 1994Date of Patent: May 28, 1996Assignee: Arizona Board of Regents acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam
-
Patent number: 5504191Abstract: Herein disclosed are several pentapeptide methyl ester derivatives of dolatin 10, using both naturally occurring and modified amino acids. The selected modified amino acids are constituents of dolastatin 10 which is a structurally distinct peptide with excellent in vitro and in vivo antineoplastic activity.Type: GrantFiled: August 1, 1994Date of Patent: April 2, 1996Assignee: Arizona Board of Regents acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam, Michael D. Williams
-
Patent number: 5494893Abstract: The cytostatic cycloheptapeptide stylostatin 2 was isolated respectively, from the South and Western Pacific Ocean sponges Stylotella sp. and Phakellia costata. Structural determination was accomplished by utilizing high-field (500 MHz) 2D-NMR experiments and confirmed by an X-ray crystal structure determination to provide the assignment cyclo(Pro-Leu-Ile-Phe-Ser-Pro-Ile). The absolute configuration was established by chiral gas chromatographic analytical technique. The cyclic heptapeptide backbone was found to include a .beta.-turn, type VIa, incorporating a cis peptide bond, at -Ser-Pro.Type: GrantFiled: November 14, 1994Date of Patent: February 27, 1996Assignee: Arizona Board of Regents, a body corporate acting on behalf of Arizona State UniversityInventors: George R. Pettit, Jayaram K. Srirangam